Authors:
SCHUCK S
ALLAIN H
GANDON JM
PATAT A
MILLET V
LECOZ F
Citation: S. Schuck et al., EFFECT OF BROMAZEPAM VERSUS PLACEBO ON INHIBITION AND WAITING CAPACITY IN YOUNG-WOMEN WITH TRAITS OF ANXIETY, Fundamental and clinical pharmacology, 12(4), 1998, pp. 463-467
Authors:
DENOLLE T
SASSANO P
PATAT A
LEBRETON S
ALLAIN H
GANDON JM
Citation: T. Denolle et al., EFFECTS OF NICARDIPINE AND CLONIDINE ON COGNITIVE FUNCTIONS AND EEG IN MIDDLE-AGED AND ELDERLY HYPERTENSIVE PATIENTS, Journal of hypertension, 16, 1998, pp. 2226-2226
Citation: Cp. Macsweeney et al., ANTIDEPRESSANT-LIKE EFFECTS OF ALNESPIRONE (S-20499) IN THE LEARNED HELPLESSNESS TEST IN RATS, European journal of pharmacology, 345(2), 1998, pp. 133-137
Authors:
ROSENZWEIG P
PATAT A
ZIELENIUK I
CIMAROSTI I
ALLAIN H
GANDON JM
Citation: P. Rosenzweig et al., COGNITIVE PERFORMANCE IN ELDERLY SUBJECTS AFTER A SINGLE-DOSE OF BEFLOXATONE, A NEW REVERSIBLE SELECTIVE MONOAMINE-OXIDASE-A INHIBITOR, Clinical pharmacology and therapeutics, 64(2), 1998, pp. 211-222
Authors:
PATAT A
KIRKESSELI S
LEFEBVRE P
CALIC F
MONTAY G
LECOZ F
GANDON JM
Citation: A. Patat et al., RILUZOLE SINGLE-DOSE PHARMACOKINETICS IN PATIENTS WITH IMPAIRED LIVER-FUNCTION, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 64-64
Authors:
PATAT A
DUBRUC C
DESCHAMP C
DURRIEU G
TROCHERIE S
CIMAROSTI I
ALLAIN H
ROSENZWEIG P
GANDON JM
Citation: A. Patat et al., EEG, MAO-A INHIBITION, PHARMACOKINETICS AND SAFETY OF BEFLOXATONE IN THE ELDERLY, Human psychopharmacology, 12(6), 1997, pp. 557-571
Authors:
EDAN G
MILLER D
CLANET M
CONFAVREUX C
LYONCAEN O
LUBETZKI C
BROCHET B
BERRY I
ROLLAND Y
FROMENT JC
DOUSSET V
CABANIS E
IBAZIZEN MT
GANDON JM
LAI HM
MOSELEY I
SABOURAUD O
Citation: G. Edan et al., THERAPEUTIC EFFECT OF MITOXANTRONE COMBINED WITH METHYLPREDNISOLONE IN MULTIPLE-SCLEROSIS - A RANDOMIZED MULTICENTER STUDY OF ACTIVE DISEASE USING MRI AND CLINICAL-CRITERIA, Journal of Neurology, Neurosurgery and Psychiatry, 62(2), 1997, pp. 112-118
Authors:
PATAT A
TROCHERIE S
LECOZ F
TROY S
BURKE J
DANJOU P
ALLAIN H
GANDON JM
Citation: A. Patat et al., ABSOLUTE BIOAVAILABILITY AND EEG EFFECTS OF CT AND ER VENLAFAXINE FORMULATION, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 62-62
Authors:
DENOLLE T
ALBERINI H
TURBIN A
CIMAROSTI I
PATAT A
GANDON JM
Citation: T. Denolle et al., DEFINITION OF BASE-LINE BLOOD-PRESSURE IN NORMOTENSIVE VOLUNTEERS, Archives des maladies du coeur et des vaisseaux, 90(8), 1997, pp. 1097-1101
Authors:
ALLAIN H
NEUMAN E
MALBEZIN M
SALZMAN V
GUEZ D
WESNES K
GANDON JM
Citation: H. Allain et al., BRIDGING STUDY OF S12024 IN 53 INPATIENTS WITH ALZHEIMERS-DISEASE, Journal of the American Geriatrics Society, 45(1), 1997, pp. 125-126
Authors:
CANNMOISAN C
CAROFF J
LEBRAS P
GIRIN E
CURET O
GANDON JM
Citation: C. Cannmoisan et al., MEASUREMENT OF 3,4-DIHYDROXYPHENYL ETHYLENE-GLYCOL (DOPEG) IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION, Journal of liquid chromatography & related technologies, 19(19), 1996, pp. 3119-3124
Authors:
PATAT A
CERCLE M
TROCHERIE S
PEYTAVIN G
POTIN C
ALLAIN H
GANDON JM
Citation: A. Patat et al., LACK OF AMPHETAMINE-LIKE EFFECTS AFTER ADMINISTRATION OF MEFENOREX INNORMAL YOUNG SUBJECTS, Human psychopharmacology, 11(4), 1996, pp. 321-335
Authors:
PATAT A
LECOZ F
DUBRUC C
GANDON JM
DURRIEU G
CIMAROSTI I
JEZEQUEL S
CURET O
ZIELENIUK I
ALLAIN H
ROSENZWEIG P
Citation: A. Patat et al., PHARMACODYNAMICS AND PHARMACOKINETICS OF 2 DOSE REGIMENS OF BEFLOXATONE, A NEW REVERSIBLE AND SELECTIVE MONOAMINE-OXIDASE INHIBITOR, AT STEADY-STATE IN HEALTHY-VOLUNTEERS, Journal of clinical pharmacology, 36(3), 1996, pp. 216-229
Authors:
LIEURY A
GERMAIN R
MENARD G
GANDON JM
ALLAIN H
Citation: A. Lieury et al., STUDY OF THE CORRELATIONS BETWEEN SELF-ES TIMATION OF MEMORY, A PSYCHOMETRIC TEST (SM9), AND A TEST OF MEMORY DAILY-LIFE EVENTS, Therapie, 51(2), 1996, pp. 131-138
Authors:
BELLISSANT E
DENOLLE T
SINNASSAMY P
BICHET DG
GIUDICELLI JF
LECOZ F
GANDON JM
ALLAIN H
Citation: E. Bellissant et al., SYSTEMIC AND REGIONAL HEMODYNAMIC AND BIOLOGICAL EFFECTS OF A NEW KAPPA-OPIOID AGONIST, NIRAVOLINE, IN HEALTHY-VOLUNTEERS, The Journal of pharmacology and experimental therapeutics, 278(1), 1996, pp. 232-242
Authors:
GANDON JM
LECOZ F
ENSLEN M
CHAUFFARD F
TACHON P
ALLAIN H
PATAT A
Citation: Jm. Gandon et al., DETERMINATION OF THE MAXIMAL TOLERATED DOSE OF A NEW ACUTE ORAL CAFFEINE FORMULATION IN HEALTHY-VOLUNTEERS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 81-81
Authors:
ALLAIN H
PATAT A
LIEURY A
LECOZ F
JANUS C
MENARD G
GANDON JM
Citation: H. Allain et al., COMPARATIVE-STUDY OF THE EFFECTS OF ZOPICLONE (7.5 MG), ZOLPIDEM, FLUNITRAZEPAM AND A PLACEBO ON NOCTURNAL COGNITIVE PERFORMANCE IN HEALTHY-SUBJECTS, IN RELATION TO PHARMACOKINETICS, European psychiatry, 10, 1995, pp. 129-135
Authors:
PATAT A
GANDON JM
DURRIEU G
LECOZ F
CURET O
CIMAROSTI I
ALLAIN H
Citation: A. Patat et al., EFFECTS OF SINGLE AND MULTIPLE DOSES OF A NEW REVERSIBLE MAO-A INHIBITOR, BEFLOXATONE, ON PSYCHOMOTOR PERFORMANCE AND MEMORY IN HEALTHY-SUBJECTS, Human psychopharmacology, 10(2), 1995, pp. 111-125
Authors:
BELLISSANT E
DENOLLE T
SINNASSAMY P
LECOZ F
GANDON JM
Citation: E. Bellissant et al., PHARMACODYNAMICS OF A NEW KAPPA-OPIOID AGONIST, NIRAVOLINE, IN HEALTHY-VOLUNTEERS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 142-142
Authors:
PATAT A
LECOZ F
GANDON JM
BECK A
DURRIEU G
CURET O
ALLAIN H
Citation: A. Patat et al., USE OF FREE DHPG PLASMA-LEVELS TO ASSESS EQUIPOTENCY OF 2 DOSAGE REGIMENS OF BEFLOXATONE, A REVERSIBLE MAO-A INHIBITOR, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 146-146